Report on Global Breast implants by DataM Intelligence estimates the market to grow at a CAGR of 6.7% during the forecast period 2023-2030.
Breast implants are the medical devices that are implanted under the breast tissue or the chest muscle to increase breast size (augmentation) or to rebuild breast tissue after mastectomy or other damage to the breast (reconstruction).
Metrics |
Details |
Market CAGR |
6.7% |
Segments Covered |
By Product Type, By Application, By End-User, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
For more insights - Download the Sample
The global breast implant market growth is driven by the increasing awareness of breast reconstruction procedure has led to higher number of women that have underwent mastectomy to opt for the procedure. Further, rising awareness of women towards breast augmentation procedures for beauty enhancement also resulted in higher breast implant adoption.
The rising prevalence of breast cancer around the world is one of the major factors for the growth of the breast implant market. According to the report of GLOBOCAN 2020, breast cancer surpassed the lung cancer and became the most diagnosed cancer around the world. According to World Health Organization, in 2020, around 2.3 million women were diagnosed with breast cancer and 685,000 of which died, globally. Also, about 7.8 million women were alive who were diagnosed with breast cancer in the last five years. While, in Asian women, the breast cancer prevalence was so high that it accounted for 22.9% of the total cancer cases in women in 2020. Another factor which will boost the growth of the studied market is increasing inclination and awareness of women all around the world towards the breast augmentation and reconstruction procedures for the beauty enhancement. For example, as per the 2019 statistics of International Society for Aesthetic Plastic Surgeons (ISAPS), there were about 1,795,551 breast augmentation procedures all over the world in 2019 which was more than any other performed aesthetic surgery.
Additionally, the market players in the area are continuously working towards better and efficient solutions and evolving the life of available products in the area through new product launches, collaborations, and mergers and acquisitions which will also complement the growth of the breast implant market. For instance, in November 2019, Evonik and BellaSeno GmBH announced a partnership agreement to develop innovative breast implant technology using RESOMER bioresorbable polymer.
However, the post-surgery complications and risk associated with the breast implant along with high cost associated with the implant are the major restraining factors for the growth of the breast implant market as there is high misconception about the post surgical complications and risks from the breast implant in the women.
The COVID-19 had a short-term impact on the breast implant market primarily in the initial phase of the pandemic when the whole world went into lockdown and other travel restrictions to curb the spread of infection due to the SARS-CoV-2 virus. Due to restrictions and lockdown, the ongoing and scheduled surgical procedures were delayed or canceled which impacted the breast implant market negatively. However, the interest and demand for beauty procedures increased during the COVID-19 period among women in the United States including breast implant and augmentation. For instance, according to the April 2021 survey report by the American Society of Plastic Surgeons, 11% of the surveyed women were more inclined towards cosmetic surgery or non-surgical procedures more than before COVID-19. Therefore, the market is expected to recover soon from the impact of the COVID-19 pandemic and grow in the future.
Silicone implants are silicone shells filled with a plastic gel (silicone) that resembles human fat because of its viscosity and are used for breast augmentation or breast reconstruction. Compared to other types of implants, they feel more natural breast tissue which is the major reason why it is the preference of the majority of people seeking breast implants as compared to other kinds. The silicone breast implants are approved for breast augmentation in women of age 22 or older and for breast reconstruction in women of any age by the United States Food and Drug Administration.
Also, the new technological advancements and improvements in the existing products of the silicone breast implant for breast augmentation and reconstruction will boost the growth of the breast implant market. For instance, in May 2021, GC Aesthetics, Inc., a silicone breast implant manufacturer, announced the launch of a next-generation breast implant called PERLE which is a smooth breast implant having the proprietary surface technology called BioQ. Thus, due to the high demand for silicone-based breast implants, the market is expected to grow during the forecast period.
North America holds a major share of the breast implant market and is expected to show a similar trend over the forecast period mainly due to the high demand for breast augmentation surgeries due to the presence of several entertainment industries in the region and self-awareness among women. In North America, the United States is expected to hold the largest market for breast implants in the region during the forecast period.
The demand for cosmetic surgeries and procedures in the United States is very high among women which is one of the major factors for the growth of the breast implant market in the region. For instance, according to the 2020 report of the American Society of Plastic Surgeons, breast augmentation was one of the top five cosmetic surgical procedures performed in 2020 in the United States, the total number was 193,073 breast augmentation procedures in 2020. The increasing prevalence of breast cancer in North America will also complement the growth of the breast implant market in the region. As per the GLOBOCAN 2020 report, the new breast cancer cases in the United States, Canada, and Mexico were 253,465: 28,026; and 29,929, respectively in 2020. Therefore, North America is expected to hold a major market share in the breast implant market during the forecast period.
The intra ocular lens market is moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AbbVie Inc. (Allergan plc), Establishment Labs SA, GC Aesthetics, Groupe Sebbin SAS, Laboratories Arion, Johnson & Johnson (Mentor Worldwide LLC), Polytech Health & Aesthetics GmbH, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the intra ocular lens market globally. For instance, in August 2020, Hair Diagnostix announced the launch of an advanced and easy-to-use self-test to detect leaking breast implants.
Overview:
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products.
Product Portfolio:
Natrelle: Breast Implants are approved for the following: Breast augmentation for women at least 22 years old for silicone-filled implants and for women at least 18 years old for saline-filled implants. Breast augmentation includes primary breast augmentation to increase the breast size and revision surgery to correct or improve the result of a primary breast augmentation
Breast reconstruction. This includes primary breast reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. This also includes revision surgery to correct or improve the result of a primary breast reconstruction.
$4350
$3750
$4350
$4350
$4350
$4350